Phase IIb multicenter clinical trial of oral suberoylanilide hydroxamic acid [vorinostat] in advanced cutaneous T-cell lymphoma.
Phase of Trial: Phase II
Latest Information Update: 06 Apr 2017
At a glance
- Drugs Vorinostat (Primary)
- Indications Cutaneous T cell lymphoma
- Focus Therapeutic Use
- Sponsors Merck & Co
- 20 Jul 2007 Final results have been published.
- 20 Jul 2007 Status changed from in progress to completed.
- 25 Sep 2005 New trial record.